


BRIEFING NOTE

52 Wk. Lo/Hi

11.60 – 23.00



SCOL (lighter line) OMX market vs price relative

Monday, 14 February 2022

Close Price (SEK)	14.92
52 wk Range Low (SEK)	11.60
52 wk Range High (SEK)	23.00
MCAP (m)	SEK 550.16
EV (m)	SEK 366.31
Index: Public	FNSE
Financial YE	31-Dec
Currency	DKK

Business Activity

Biotechnology

Key Metrics

Gross debt (m)	DKK 0.0
Cash (m)	DKK 117.3
Net Debt (Cash) (m)	-DKK 117.3
Net Operating Cash (m)	-DKK 43.7
Revenue (m)	DKK 0.0
Net Income (loss) (m)	-DKK 41.8

Key Ratios

(Net Cash) / Shareholder Equity %	-21.32%
-----------------------------------	---------

Biotechnology Sector Research

FNSE Market Index

ACF Biotechnology Team

+44 20 7419 7928
biotechnology@acfequityresearch.com

Scandion Oncology A/S

Core Investment Case

Scandion Oncology A/S (SCOL: FNSE) is a Denmark-based biotechnology company focused on developing drugs to treat cancers that have developed resistance to existing medical protocols. SCOL targets the resistance of cancer drugs for various treatments including chemotherapy, anti-hormonal therapy and immunotherapy. The company's lead drug candidate, SCO-101 is in Phase Ib (PANTAX) and Phase II (CORIST) clinical trial. Important to note that, there are currently no drugs in the market targeting cancer drug resistance, which could make SCO-101 a first-in-class treatment for a large unmet medical need.

- Nil revenue - SCOL is yet to commercialize any drug;
- Net loss of DKK15.3m for 3Q21A;
- Cash & cash equivalents at ~DKK117.3m as of the end of 3Q21A;
- Drug R&D for cancers resistant to current protocols.

*MCAP and EV figures are in SEK million

DKK (m)	MCAP	EV	RoA %	RoE %	NCO	Levered FCF
2022	550.16	366.31	-44.79%	-66.09%	-43.7	-30.9
Multiples	EV/ Revs	P/ S	Trail PE	BV/ Share	P/ B	Current
2022	N/A	N/A	N/A	3.71	3.3x	12.01x

Investment Case

Clear path to market – Scandion Oncology has two programs in clinical development with its lead compound SCO-101 – CORIST for **metastatic colorectal cancer** and PANTAX for **pancreatic cancer**.

CORIST is SCOL's more advanced program targeting drug resistant metastatic colorectal cancer (mCRC) and is currently in part 2 of its proof-of-concept PII study. The data from CORIST is expected to be released in 2Q/3Q22.

SCO-101 Programs – CORIST and PANTAX

- **CORIST (SCO-101)** - Following the proof-of-concept study, the company is expected to begin pivotal PIII study as early as 2023. SCOL could get approval for SCO-101 as an mCRC drug treatment and market launch by 2027E.
- **PANTAX (SCO-101)** - The PANTAX P1b top line data is expected 2Q/3Q22.

Scalable product: Scandion Oncology is developing two products, SCO-101 (CORIST and PANTAX programs) and SCO-201, and ~800 analogues. SCO-101 is undergoing two clinical studies, while SCO-201 is in a preclinical trial. SCO-201 targets solid cancers such as ovarian cancer and non-small lung cancer (NSLC). Potential indications for the analogues are also for solid tumours. Both drug candidates are under 15–16-year patent protection i.e. until 2036/2037.

Addressing a large unmet medical need: Cancer drug resistance is one of the main challenges in the clinical management of cancer patients. Nearly 90% of all cancer related deaths are due to drug resistance.

Chemotherapy, which is the primary modality of treatment for cancer patients is a \$37bn market and is expected to reach \$56bn by 2024, a CAGR of 12%. Scandion's current pipeline targets nearly 60% of currently used chemotherapies, suggesting a large addressable market.

As there are no available treatments in the market targeting cancer drug resistance, SCOL has an opportunity to capture a significant unmet medical need.

Catalysts

CORIST Phase II Proof of concept study, PANTAX Phase Ib study read-out, Pivotal study initiation in 2023. Increasing expected growth in cancer cases.

Operational Strategy

Scandion Oncology's strategy is to develop drugs for cancer patients who become resistant to currently available cancer treatments.

The company's lead drug candidate, SCO-101 is targeted at colorectal and pancreatic cancers. There are currently no treatments in the market targeting cancer drug resistance and SCO-101 could become the first-in-class drug for this treatment.

In addition to its lead drug SCO-101, SCOL is developing SCO-201 to target other solid tumours.

Scandion's current focus is the Phase III study of SCO-101 - for patients with mCRC with 'RAS wild-type (WT)' tumours. In the pivotal study, Scandion Oncology is aiming to make SCO-101 the second line of treatment for mCRC versus the last line mCRC treatment as per the Phase II trial. If successful, this will increase the market for SCO-101 by 5x compared to last line of treatment.

Scandion is seeking to expand the clinical application of SCO-101 for patients treated with Irinotecan, the standard chemotherapy treatment given to mCRC patients.

The novel Irinotecan drugs are now positioned for indications other than mCRC such as bladder cancer, small cell lung cancer (SCLC) and breast cancer (SCLC and breast cancer are in the top five [5] cancer markets globally by value and occurrence). This provides scope for using SCO-101, combined with Irinotecan, for indications other than mCRC.

SCOL plans to enter into strategic partnerships with relevant pharma companies to commercialize SCO-101. Additionally, Scandion is aiming to position its drug candidates as add-on drugs to other modalities such as immuno-oncology.

Management Team

➤ **CEO, Bo Rode Hansen.**



Bo Rode Hansen is the CEO of Scandion Oncology since October 2020. Prior to this, Bo worked for various biotechnology companies. Bo is the founder of Genevant Sciences Inc. and has also worked as Global Head of Roche RNA Therapeutics and General Manager of Roche Innovation Centre as well as VP & Head of Drug Discovery & Alliance at Santaris Pharma. He has a MSc in Biochemistry and a PhD in Pharmaceutical Sciences from University of Copenhagen.

➤ **CFO, Johnny Stilou.**



Johnny is the CFO of Scandion Oncology since June 2021. He has extensive experience working with Danish and international listed companies. Prior to Scandion, Johnny held numerous executive positions including Chief Financial Officer within the biotech and pharma industry. Prior to joining Scandion, he was CFO at Amgen Research Copenhagen and Nuevolution AB (acquired by Amgen) and CFO of Veloxis Pharmaceuticals (acquired by Asahi Kasei).

Notes [Intentionally Blank]

INDEPENDENCE & DISTRIBUTION

ACF Equity Research Ltd is a provider of issuer-pays research with a clearly defined independent ethic. ACF produces accurate, clear, focused research aimed at a professional investment audience. ACF has excellent distribution capabilities and always aims to provide access without restriction to the widest professional audience. ACF offers a range of additional services to support its clients.

DISCLAIMER

This communication is for informational purposes only. It is not intended as an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. [The opinions expressed in this report herein do not take into account individual investor circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein.] ACF Equity Research Ltd has based this document on information obtained from sources it believes to be reliable, but which it has not independently verified. Neither ACF Equity Research Ltd. nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice. [Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by ACF Equity Research Ltd. with respect to future performance. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.]

IMPORTANT DISCLOSURES FOR U.S. INVESTORS

This research report was prepared by ACF Equity Research Ltd., a company authorized to engage in securities activities in the United Kingdom. ACF Equity Research Ltd. is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended. Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through, a registered broker-dealer in the United States. The analyst who prepared this research report is not registered or qualified with the Financial Industry Regulatory Authority ("FINRA") and may not be associated with a U.S. broker dealer and as such, would not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

[Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.]

LEGAL NOTICE

This report is for authorized use by the intended recipient(s) only. It may contain proprietary material, confidential information and/or be subject to legal privilege. No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of ACF Equity Research Ltd. and ACF Equity Research Ltd. accepts no liability whatsoever for the actions of third parties in this respect.

IMPORTANT ADDITIONAL DISCLOSURES FOR U.K. INVESTORS

The information in this report has been prepared by ACF Equity Research Ltd (ACF). The research is published for information purposes only. It is not intended as an offer or solicitation for the purchase or sale of any securities or any financial instruments.

ACF has based this document on information obtained from sources it believes to be reliable but which it has not independently verified. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice. Any comments or statements made herein do not necessarily reflect those of ACF Equity Research Limited. The material should not be regarded by recipients as a substitute for the exercise of their own judgment. Past performance does not guarantee future performance.

The analyst(s) responsible for covering the securities in this report receive compensation based upon, among other factors, the overall profitability of ACF which may, from time to time, solicit business from any of the companies referred to in this report. The analyst(s) responsible for covering securities in this report may not hold a position in any or related securities in this report in ACF's sector universe or in any other sector in which ACF carries out research. The company does not hold any position in the securities mentioned in this report.

This research report and its contents are intended for professional investors and not for retail investors. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of the investment research. ACF Equity Research Limited is authorised and regulated by the Financial Conduct Authority. However the contents of this research report are produced as if ACF Equity Research Limited is unregulated and consequently this report does not contain investment recommendations or ratings.

ACF, its directors, employees and agents accept no liability whatsoever for any loss or damage of any kind arising out of the use of all or part of these materials. The information in this report is provided with the understanding that ACF is not acting in a fiduciary capacity. Certain laws and regulations impose liabilities which cannot be disclaimed. This disclaimer shall in no way constitute a waiver or limitation of any rights a person may have under such laws and/or regulations. Copyright © 2018 ACF Equity Research all rights reserved. Additional information is available upon request.

Copyright 2018 ACF Equity Research Ltd. All rights reserved.

ACF Equity Research Limited, 125 Old Broad Street, London, EC2N 1AR, U.K.

Tel: +44 (020) 7558 8974

Website: www.acfequityresearch.com